Preclinical biotechnology company Omniose announced on Tuesday that it has been acquired by biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN).
This acquisition brings Omniose's proprietary bioconjugation technology and expertise into AstraZeneca's Infectious Disease Unit.
It follows a three-year exclusive research collaboration between the two companies.
Under the agreement, Omniose becomes a wholly owned subsidiary of AstraZeneca, supporting the development of preclinical vaccine programmes and complementing the company's existing capabilities in bacterial vaccines.
Omniose's bioconjugation platform enables bacterial polysaccharides and engineered carrier proteins to be produced and linked within a single cell, potentially simplifying conjugate vaccine manufacturing and improving molecular precision and vaccine quality.
AstraZeneca said the technology strengthens its ability to develop novel vaccines against serious bacterial infections.
Omniose
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology